Dr. Andrew Mahan

Janssen: Pharmaceutical Companies of Johnson & Johnson

Semi-targeted spent media LC-MS assay: Assuring product quality during cell line development for biologics

Watch this presentation by Dr. Andrew Mahan, Associate Director at Janssen: Pharmaceutical Companies of Johnson & Johnson, titled: Semi-targeted spent media LC-MS assay: Assuring product quality during cell line development for biologics. This talk was presented at the SelectScience® Virtual Biopharmaceuticals Summit 2022.



LIKE 0
Dr. Andrew Mahan

Dr. Andrew Mahan

Biography

Andrew D. Mahan is an Associate Director and Mass Spec Group Leader for Cell Engineering and Analytical Sciences Group at Janssen More

Dr. Andrew Mahan

Janssen: Pharmaceutical Companies of Johnson & Johnson

Andrew D. Mahan is an Associate Director and Mass Spec Group Leader for Cell Engineering and Analytical Sciences Group at Janssen. In this role, he provides analytical support through protein characterization for cell line development and high-producing manufacturing cell lines. The group facilitates biologics discovery and development by providing innovative mass spectrometry approaches. Andrew received his M.S. and Ph.D. in Analytical Chemistry from Drexel University and has been with J&J-Janssen since 1997. He is enthusiastic and passionate about mass spectrometry and its role in bringing new medicines to patients. His mission and focus are on the continuous improvement of mass spectrometry instruments and methods as well as the flawless execution of analytical methods, therefore, helping advance the work of the organizations and teams of which he's a part.